Weeks 1–4
Reported loading phase; not a clinical study period.
Protocol / Research Dosing Guide
Klow Blend Dosage Guide: Community Schedule, Reconstitution and Safety
An evidence-organized guide to the four-component Klow research blend, clearly separating community practices from evidence about its individual ingredients.
Last reviewed September 15, 202620 minute readResearch information only
Level 1 — Blend not directly studiedCommunity protocol onlyNot FDA approved
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Quick Start
Klow is a trade name for a pre-mixed product reported to contain GHK-Cu, BPC-157, TB-500, and KPV. No published study has tested the four peptides together, their fixed ratio, or their interactions.
Why researchers care
Combined repair and inflammation research claims
Class
Vendor-defined four-peptide blend
Route reported
Subcutaneous use is community reported
Cycle length
8–12 weeks reported; not validated
Regulatory status
Not FDA approved; research-use product
Loading supplier information
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Dosing Protocol and Schedule
The supplied source reports an 80 mg vial and a loading/maintenance pattern. These values are vendor/community reported; they are not clinical parameters and do not establish an appropriate human protocol.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Weeks 1–4 | 4 mg total blend | Five times weekly; community reported |
| Weeks 5–12 | 2 mg total blend | Three times weekly; community reported |
| Alternative step-up | 2.67–5.34 mg total blend | Daily escalation using 3 mL; community reported |
No trial validates the mixture, fixed ratio, frequency, cycle, rest period, or step-up pattern.
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Reconstitution Calculator
Vial-format concentration math
Concentration
40 mg/mL
Draw volume
0.1 mL
U-100 units
10
Mathematical draws
20
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow): Morning or Night?
Morning or evening?
Morning use is community reported; no preferred time is established.
Daily or several times weekly?
Both appear in community schedules; neither is validated.
With food?
Not applicable to the reported vial route and not established.
Missed amount?
No validated replacement or doubling procedure exists.
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Route Comparison
| Route | What is reported | Evidence limit |
|---|---|---|
| Subcutaneous | Community use of the fixed blend | No blend-level study |
| Topical | GHK-Cu component research exists | Does not establish topical Klow |
| Oral | Not established | No blend exposure data |
| Route conversion | None available | Component routes are not interchangeable |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Blend half-life | Not established | No combination PK study |
| GHK-Cu | Not established for this blend | Secondary estimates are not blend data |
| BPC-157, TB-500, and KPV | Not established in humans for this blend | Component evidence is incomplete |
| Frequency | Community reported | Not experimentally validated |
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous blend | 4 mg total | Five times weekly for 4 weeks | Community report | No |
| Subcutaneous blend | 2 mg total | Three times weekly for 8 weeks | Community report | No |
| Subcutaneous blend | 2.67–5.34 mg total | Daily step-up | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Reconstitution Guide
Concentration: 40 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 4 mg | 0.1 mL | 10 units |
| 8 mg | 0.2 mL | 20 units |
| 12 mg | 0.3 mL | 30 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Works
GHK-Cu component
Laboratory and dermatology research exists, but it does not test injectable Klow.
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Human Trials and FDA Status
Current status · verified September 15, 2026
Not FDA approved; research-use product
- No human trial of the Klow blend was identified.
- No animal study of the four-component blend was identified.
- Component evidence spans laboratory, animal, and limited human contexts but cannot be pooled into a blend evidence level.
- No pharmacokinetic-interaction or dose-response study of the mixture exists.
- Klow has no FDA-approved indication.
Who Should Avoid BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow)?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No blend safety data
Children or adolescents
No blend safety data
Active or recent cancer
Growth and angiogenesis concerns are unresolved
Copper metabolism disorders
The product includes a copper peptide
Concurrent medicines
No interaction studies
Long-term or repeated use
No safety data
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Side Effects, Risks and Safety
Injection-site rednessCommunity reported
Important limitation: No controlled incidence data.
Drowsiness, warmth, nausea, or headacheCommunity reported
Important limitation: Attribution to components is speculative.
Immune reactionUnknown
Important limitation: Four-component immunogenicity is uncharacterized.
Copper-related effectsUnknown for blend
Important limitation: Exposure and interactions are unstudied.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Timeline and Monitoring
Weeks 5–12
Reported maintenance phase; not validated.
Reported rest period
Four to eight weeks is community convention; restart criteria are not established.
Monitoring
No validated blend biomarker panel, stopping rule, or follow-up schedule exists.
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Tissue repair | Not established for blend | Inferred from component research | No combination study |
| Inflammation | Not established for blend | KPV and other component models | No blend validation |
| Skin or collagen outcomes | Not established for blend | GHK-Cu context | Route and formulation differ |
| Combined synergy | Not established | Vendor mechanistic narrative | No interaction study |
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Storage and Handling
Unreconstituted vial
No Klow-specific stability study was identified; follow the exact label.
Prepared vial
Community 2–8°C and 28-day guidance is not validated stability evidence.
Four-component mixture
Co-formulation compatibility and degradation are not established.
Appearance
Cloudiness, discoloration, or particles do not establish sterility or usability.
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Troubleshooting
The solution looks abnormal
Stop and seek qualified product guidance; appearance cannot confirm sterility.
The units differ from a source chart
Confirm whether the chart uses 2 mL or 3 mL and whether mg means total blend.
Per-component quantities are unclear
Use only the exact documented product ratio; do not infer composition.
A component study is used as blend proof
Return to the study product; evidence does not transfer.
A scheduled amount is missed
No validated missed-amount procedure exists.
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Klow | Four-component vendor blend | No direct studies | Not approved |
| Wolverine | BPC-157 + TB-500 blend | No direct studies | Not approved |
| GHK-Cu | Copper tripeptide | Laboratory, animal, and dermatology context | Not approved as Klow |
| KPV | Alpha-MSH fragment | Laboratory and animal research | Not approved |
BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow) Frequently Asked Questions
What is Klow?
A vendor/community name for a fixed blend of GHK-Cu, BPC-157, TB-500, and KPV.
Has the blend been studied in humans?
No.
Has it been studied in animals?
No study of the four-component product was identified.
Is it FDA approved?
No.
What is its half-life?
Not established.
Is the loading schedule validated?
No. It is community reported.
Can component studies prove Klow works?
No. Evidence stays with the exact studied molecule and route.
Is the 50/10/10/10 ratio clinically validated?
No.
Is a rest period established?
No.
What does the calculator do?
It performs total-blend concentration and volume arithmetic only.
Sources and Research
Coverage source
1. Klow blend dosing guide
Coverage source for composition and community protocol; not primary blend evidence.
Open direct sourceComponent research
2. KPV suppresses intestinal inflammation
Component-only laboratory and animal research; does not test Klow.
Open direct sourceRelated-compound human research
3. Thymosin beta-4 for dry eye
Human research on full-length thymosin beta-4, not commercial TB-500 or Klow.
Open direct sourceComponent animal research
4. Pharmacokinetics of BPC157 in rats and dogs
Component-only animal PK; does not establish blend exposure.
Open direct sourceMissing information flagged for review
- Blend identity and pharmacology study: Not established
- Human or animal blend evidence: Not established
- Blend dose, route, and frequency: Not established
- Blend pharmacokinetics and half-life: Not established
- Validated cycle and rest period: Not established
- Four-component stability: Not established
- Long-term safety: Not established
- Drug and component interactions: Not established